March 14, 2017, Vol 317, No. 10, Pages 987-1090
Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara–Vectored Ebola Vaccines at 1 Year
Rebecca L. Winslow, MRCGP; Iain D. Milligan, MRCP; Merryn Voysey, MBiostat; et al.
JAMA. 2017;317(10):1075-1077. doi:10.1001/jama.2016.20644
This study reports 1-year data from a randomized clinical trial testing the safety and immunogenicity of a novel adenovirus type 26 and modified vaccinia virus Ankara-vectored Ebola vaccines.
The Ebola virus vaccine strategies evaluated by the World Health Organization in response to the 2014-2016 outbreak in West Africa included a heterologous primary and booster vaccination schedule of the adenovirus type 26 vector vaccine encoding Ebola virus glycoprotein (Ad26.ZEBOV) and the modified vaccinia virus Ankara vector vaccine, encoding glycoproteins from Ebola, Sudan, Marburg, and Tai Forest viruses nucleoprotein (MVA-BN-Filo). This schedule has been shown to induce immune responses that persist for 8 months after primary immunization, with 100% of vaccine recipients retaining Ebola virus glycoprotein-specific antibodies.1